✓ Editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Drug Reference

Wegovy

Released: Last reviewed:

Brand name for semaglutide 2.4 mg, FDA-approved for chronic weight management and cardiovascular risk reduction in adults with overweight/obesity + established CVD.

By Novo Nordisk
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 20, 2026 · This page is informational and does not constitute medical advice.

Wegovy overview

Brand name for semaglutide 2.4 mg, FDA-approved for chronic weight management and cardiovascular risk reduction in adults with overweight/obesity + established CVD.

Wegovy at a glance

Manufacturer
Novo Nordisk
FDA status
FDA-approved

Related pages

Key facts, checked November 20, 2026

The Wegovy label covers weight management in adults and patients 12 and older with obesity, and lowering cardiovascular risk in adults with heart disease and obesity or overweight, the use tested in SELECT (NEJM 2023). It starts at 0.25 mg weekly and steps up every four weeks to a 2.4 mg (or 1.7 mg) maintenance dose. The NovoCare self-pay page, read November 20, 2026, lists the pen at $349 a month, with $199 for each of the first two fills for new patients through December 31, 2026. Medicare’s GLP-1 Bridge covers Wegovy for eligible enrollees at $50 a month, per the Medicare.gov GLP-1 Bridge page.